Watch ELDN. Know when insiders buy.
One email the day a filing lands. Free.
ELDN
Eledon Pharmaceuticals, Inc.
2.78
+0.00 +0.00%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
47
WATCH · shorts 47
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $225.9MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$98.6M −773.1%NET CASH —52W 1.39 – 4.36SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$22.9M | −$31.6M | — | -0.27 | −$22.7M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$21.2M | −$39M | — | -0.33 | −$22.6M | — | — | Aug 13 |
| Q4 2025 · Dec 31derived | — | — | — | — | −$10.4M | — | -0.10 | −$14.1M | — | — | Mar 19 |
| Q3 2025 · Sep 30 | — | — | — | −$19.1M | −$17.5M | −122.7% | -0.21 | −$14.5M | — | — | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$24.7M | −$11.2M | — | -0.13 | −$17.7M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$18M | −$6.5M | — | -0.08 | −$16.1M | — | — | Aug 13 |
| Q4 2024 · Dec 31derived | — | — | — | — | −$44.6M | — | 0.57 | −$19M | — | — | Mar 19 |
| Q3 2024 · Sep 30 | — | — | — | −$20.5M | $77M | — | -0.28 | −$11.8M | — | — | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$14.5M | −$44.9M | — | -0.92 | −$7.8M | — | — | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | −$10.9M | −$23.6M | — | -0.65 | −$8.7M | — | — | Nov 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$10.3M | −$30.1M | — | -0.94 | −$9.1M | — | — | Aug 14 |
| Q3 2023 · Sep 30 | — | — | — | −$11.2M | −$9.9M | — | -0.33 | −$12.3M | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | — | −$45.6M | — | -0.52 | −$62.3M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | — | −$36.2M | — | -0.66 | −$47.3M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$43M | −$116.5M | — | -4.73 | −$39.5M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$88.4M | −$88M | — | -6.16 | −$28.4M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$36.9M | −$34.5M | — | -2.33 | −$28.9M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$18.5M | −$22.8M | — | -15.72 | −$15.2M | — | — | — | — |
Every number comes from Eledon Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.